MS victims denied vital drug due to the high cost
The West Australian - Perth,Western Australia,Australia
Under a Pharmaceutical Benefits Scheme ruling, people with MS will miss out on the drug, Tysabri, unless they can pay more than $30000 a year when it ...
See all stories on this topic

Elan and Biogen Idec Announce a FDA Advisory Committee Meeting and ...
Financial News USA (press release) - La Puente,CA,USA
In the US, TYSABRI is approved as a monotherapy treatment for relapsing forms of MS. MedImmune, Inc. (Nasdaq: MEDI) recently announced that the US Food and ...
See all stories on this topic